source
- Eli Lilly stops disclosing Phase 1 pipeline, prompting mixed reactionsEli Lilly announced that it will no longer publicly share details of its Phase 1 drug candidates. The policy shift comes as the company’s GLP-1 product continues to generate the highest sales among…
- CMS GLP-1 pilot shows early uptake and health benefits for seniors, signaling broader weight-loss drug accessCMS launched a federal pilot program to expand access to GLP-1 weight-loss medications for seniors. After about two months, early data show that enrollment is rising and participants report improv…